Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 16;20:105. doi: 10.1186/s12964-022-00882-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — Inhibition of glycolysis enhanced the anticancer effects of penfluridol. A, B The glucose consumption and lactic ability of SGC-996, EH-GB1, and GBC-SD cells treated with PF as indicated for 24 h. C, D The glucose consumption and lactic ability of SGC-996, EH-GB1, and GBC-SD cells treated with control, 2-DG (2 mM), PF (5 μM), or 2-DG + PF. E The colony formation of SGC-996, EH-GB1, and GBC-SD cells treated with controls, 2-DG (1 mM), PF (1 μM), or 2-DG + PF for 14 days. F Annexin V/PI apoptosis assay of SGC-996, EH-GB1, and GBC-SD cells were with control, 2-DG (2 mM), PF (5 μM), or 2-DG + PF for 24 h before Annexin V/PI assay. G Western blot of SGC-996, EH-GB1, and GBC-SD were treated with control, 2-DG (2 mM), PF (5 μM), or 2-DG + PF. **P < 0.01, ***P < 0.001, ****P < 0.0001